Relationship between serum lipid level and meibomian gland dysfunction subtype in Korea : A propensity score analysis

Minji Ha

The Catholic University of Korea

Jiyun Song

The Catholic University of Korea

Sunkyoung Park

The Catholic University of Korea

Kyungdo Han

Soongsil University

Ho Sik Hwang

The Catholic University of Korea

Hyun-Seung Kim

The Catholic University of Korea

Reiko Arita

Keio University

Kyung-Sun Na (✉ dma@catholic.ac.kr)

The Catholic University of Korea

Research Article

Keywords: High-density lipoprotein, Low-density lipoprotein, Meibomian gland dysfunction, Serum lipid level, Total cholesterol, Triglyceride

Posted Date: May 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-409763/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on August 9th, 2021. See the published version at <https://doi.org/10.1038/s41598-021-95599-y>.

Abstract

Purpose: To analyze the correlation between systemic lipid profile levels and each meibomian gland dysfunction (MGD) subtype in Korea.

Methods: The ophthalmic data of 95 eyes and the serum lipid profiles of 95 patients were reviewed. These factors were compared with those of the general population using data from the Korean National Health and Nutrition Examination Survey (KNHANES), which evaluated 2,924 subjects. Of these, 475 propensity score-matched normal controls were selected for comparison with the 95 MGD patients based on a 1:5 ratio. In addition, we analyzed the correlations between serum lipid profile levels and MGD subtypes in MGD patients.

Results: The mean high-density lipoprotein (HDL) value of the MGD patients was significantly higher than that of the general population ($P < 0.0001$). However, the mean total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL) levels of the MGD patients were not significantly different from those of the general population (TC: $P = 0.3950$, TG: $P = 0.6331$, LDL: $P = 0.2079$). In addition, no serum lipid levels statistically differed among the MGD subtypes (TC: $P = 0.7650$, HDL: $P = 0.2480$, LDL: $P = 0.3430$, TG: $P = 0.7030$).

Conclusion: A statistically significant, but marginal, increase in HDL concentration was observed in the MGD group, although there was no difference in any serum lipid level among the MGD subtypes.

Introduction

Chemical analyses of lipids secreted from normal meibomian glands (MGs) have revealed a mixture of non-polar lipids (sterols and wax esters), as well as small numbers of polar lipids (phospholipids and glycolipids)^{1,2}. Previous studies have demonstrated that meibomian gland dysfunction (MGD) patients exhibit elevated concentrations of cholesterol esters in meibum samples compared to those of healthy controls^{1,2}. Although normal meibum lipids have a melting point of 30–34 °C³, the melting point increases to 46°C as the viscosity increases due to elevated cholesterol concentrations⁴. Because MGs are lipid-synthesizing organs, it is plausible that altered systemic lipid metabolism could affect their physiology and structure.

Dyslipidemia is a disorder of systemic lipid metabolism that is characterized by abnormally elevated total blood cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL) levels, and/or a reduction in the level of high-density lipoproteins (HDLs). Dyslipidemia is one of the major modifiable risk factors in cardiovascular disease, which is a major cause of death in adults. Previous studies have suggested that dyslipidemia may be related to the development of MGD; however, the current evidence is inconclusive. Moreover, no previous studies have revealed any relationship between dyslipidemia and any of the MGD subtypes in East Asian populations. Determining whether pathological concentrations of systemic lipids contribute to the various subtypes of MGD would fill a gap in our understanding of the disease. Therefore, the current study aimed to assess correlations between systemic lipid profile levels and each MGD

subtype. We further compared each systemic lipid value in MGD patients with those of the general population using the nationally representative data of the Korea National Health and Nutrition Examination Survey (KNHANES).

Materials And Methods

Study population

This retrospective, observational study was approved by the institutional review board of Yeouido St Mary's Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki. Based on the approval, written informed consent from each subject was waived by the institutional review board/ethics committee of Yeouido St Mary's Hospital. We reviewed the charts of patients who were diagnosed with MGD by a single examiner (N.K.S) between January 2019 and October 2020. Treatment of MGD patients often includes the supplementation of an omega-3 fatty acid, which is known to alter lipid levels; therefore, baseline lipid profiles were conducted at the time of the initial visit for all MGD patients, which included assessments of HDL, LDL, TG, and TC concentrations. All ophthalmic data were also collected during the first visit to the ophthalmology department.

Patients were diagnosed with MGD via clinical examinations based on descriptions of glandular obstruction and meibum quality. Digital pressure over the central third of the lower eyelid was used to evaluate gland obstructions, and meibum secretion quality was assessed via slit-lamp biomicroscopy. Each patient's lipid profile was assessed at the time of diagnosis. The exclusion criteria were as follows: (1) rheumatic, neurological, or dermatological diseases affecting the condition of the ocular surface; (2) a history of ocular surgery within one month prior to the initiation of the study; (3) any signs of ocular infection (bacterial or viral); (4) concomitant use of topical ophthalmic medications; and (5) any known history of dyslipidemia and/or the regular use of anti-hyperlipidemia drugs.

Since there is a lack of data pertaining to ophthalmic examinations and profiling of serum lipid levels for normal controls, we used as a comparator the data of 7,225 subjects in the general population that were collected in 2012 as part of the KNHANES, a survey conducted by the Division of Chronic Disease Surveillance under the guidance of the Korea Centers for Disease Control and Prevention. Among these, subjects who were aged <19 years; received glaucoma treatment; or were diagnosed with thyroid disease, arthritis, atopy, facial nerve palsy, or dry eye disease (DED) were excluded; thus, 2,942 subjects were remained. Ultimately, 475 age- and sex-matched control individuals from the general population were included in this study by applying a 1:5 propensity score matching method (Fig. 1).

The Korea National Health and Nutrition Examination Survey (KHANES), a questionnaire related to DED, was distributed, comprising the following items: "(1) Have you ever been diagnosed with DED by an ophthalmologist?" and "(2) Do your eyes tend to be dry, with a foreign body sensation including itching and burning or sandy feeling lately?" These questions could be answered as "yes" or "no." If a participant answered "yes" to the first question, he/she was classified as "diagnosed with DED," and if they answered "yes" to the second question, as "having symptoms of DED." If a participant answered "no" to the

questions, he/she was classified as a control. Subjects diagnosed with DED or as having symptoms of DED were excluded from this study. Participants who answered “do not know” were excluded from the analysis.

The age, sex, and serum lipid profiles (including TC, HDL, and TG levels) of the MGD patients were compared to those of the general population. However, LDL levels were excluded from the control group items because the 2012 KNHANES did not investigate them. Therefore, we additionally examined LDL level data from the general population from a survey conducted in 2015 for comparison with the LDL levels in the MGD patients; these data are marked with an * in each table.

Peripheral blood was obtained from each subject after fasting for at least eight hours; this applied to both the MGD patients who were assessed in a single department and the normal controls in the KHANES. Serum TC, HDL, and TG concentrations were enzymatically quantified by the same methodology using a Hitachi Automatic Analyzer 7600 (Hitachi/Japan) with reagents (Pureauto SCHO-N, DAIICHI/Japan; CHOLESTEST N HDL, DAIICHI/Japan; Pureauto S TG-N, DAIICHI/Japan) at the NEODIN Medical Institute. The LDL concentration was calculated using the Friedewald equation ($LDL = TC - [HDL + \{TG \div 5\}]$).

Clinical examinations

Each participant underwent a thorough ophthalmic examination. The following objective tests for MGD were performed: Ocular Surface Disease Index (OSDI) questionnaire, slit-lamp examination of the ocular surface to assess the tear break-up time (TBUT) and corneal fluorescein staining, lid margin examination, MG expressibility/duct assessment, and noncontact meibography. A 5-minute interval or longer was allotted between each test, except between the administration of the OSDI questionnaire and the slit-lamp examination. The OSDI questionnaire assessed symptoms on a scale ranging from 0 (no symptoms) to 100. Corneal staining was conducted using fluorescein sodium-impregnated paper strips (Haag-Sterit, Bern, Switzerland). The strips were wetted with normal saline, and diluted dye was instilled into the ocular surface. After gentle blinking, the degree of corneal staining was graded according to the Oxford scoring scheme (range of 0–5 points). TBUT, the interval between blinking and the first appearance of a dry spot on the tear film, was measured using a stopwatch.

Eight MGs in the central third area of the lower eyelid were tested for meibum expressibility and secretion following application of firm digital pressure. The meibum quality was scored according to the following criteria, which were modified from the meibum quality grading system described by Mathers et al.¹⁶: 0 = normal; 1 = yellow in color, without increased viscosity; 2 = yellow in color, with increased viscosity; 3 = toothpaste-like consistency; 4 = no meibum.

Meibography images were acquired using non-contact infrared meibography. The degree of MG loss was classified according to the meiboscore described by Arita et al.¹⁷ on a scale of 0–3, as follows: 0: no loss of MGs; 1: area loss < one-third of the total MG area; 2: area loss between one-third and two-thirds of the total MG area; 3: area loss > two-thirds of the total MG area. MGD was classified into stages ranging from 1 to 4 according to the MGD stage classification criteria published in 2011 by an international workshop

on MGD¹⁸. Blood laboratory tests of baseline lipid profiles, including quantification of TC, TG, HDL, and LDL levels, were performed.

Patient classification

MGD patients were classified into three groups according to the modified classification of Xiao et al.¹⁹ and Eom et al.²⁰. Subjects with a meibum expressibility score greater than 5 were classified as having high-delivery MGD, whereas those with a meibum expressibility score lower than 5 were classified as having low-delivery MGD. The obstructive and hyposecretory subtypes of low-delivery MGD were classified according to the meibum quality and signs of lid margin inflammation.

Statistical analysis

Propensity score matching at a ratio of 1:5 was used to select the individuals comprising the normal control group from the KNHANES data to compare with the data from the MGD patients. The propensity score is the probability of receiving active treatment ($Z=1$ vs. $Z=0$), conditional on the observation of baseline covariates²¹. It is a balancing score; in other words, conditional on the propensity score, the distribution of measured baseline covariates is expected to be the same in treated and untreated subjects²². In observational studies, in order to overcome the shortcomings of the classical matching method and to minimize selection bias, a matching method using a propensity score is used. Similar to randomized, controlled trials (RCTs), propensity score methods allow one to estimate marginal, rather than conditional, measures of treatment effects²³. The reason for this can be clearly seen for matching, stratification, and weighting, as one is comparing average outcomes between samples of treated and untreated subjects exhibiting the same distribution of observed baseline covariates²². After propensity score matching, t-tests were used to compare the variables (age, age distribution, sex, and lipid profile values) between the two groups.

One sample t-tests were performed to compare lipid profile values. One sample z-tests were used to compare the distribution of patients with abnormal lipid levels with those of the general population according to age range.

Clinical parameters and lipid profile values were compared among the MGD subtypes using the Kruskal–Wallis H test with Dunn-Bonferroni *post hoc* tests. Values are expressed as means and standard deviations. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) ver. 22.0 software (IBM Corp., Armonk, NY, USA) and SAS 9.1.3 (SAS Institute, Cary, NC).

Results

Given the ethnic composition of Korean society, all of the subjects were East Asian. A total of 95 MGD patients were included in this study, with a mean age of 57.5 ± 13.2 years (range: 19–86 years), 84.2% of whom were women and 15.8% of whom were men. We stratified our patients into age brackets; 32.7% of

the MGD patients were aged > 65 years, 49.5% were aged 45–64 years, and 16.8% were younger than 45 years. The mean age of the control patients in the general population selected from the KNHANES through propensity score matching (1:5) was 56.4 ± 12.7 years (range: 19–80 years); 28.2% were over 65 years old, 53.9% were 45–64 years of age, and 17.9% were under 45 years of age. Of these, 85.3% were women and 14.7% were men. There were no statistically significant differences between the two groups based on age or sex ($P = 0.8722$, $P = 0.5613$, and $P = 0.7926$ for mean age, age distribution, and sex, respectively) (Table 1). Additional demographic information of the general population group prior to propensity score matching is provided as supplementary information (Supplementary Table 1).

The MGD patients had high levels of HDL (63.1 ± 14.7 mg/dL). In the control patients, the HDL level was 52.1 ± 12.5 mg/dL, which was within the normal range. There was a statistically significant difference in the HDL levels between the two groups ($P < 0.0001$). No statistically significant differences were observed for the mean TC ($P = 0.4685$) and TG ($P = 0.5530$) levels between the two groups, and the average values of both groups were within the normal ranges. Compared to the mean LDL levels of the control group based on the KNHANES data from 2015, the mean LDL values of the MGD group did not significantly differ ($P = 0.0713$) (Table 1, Fig. 2).

In the MGD patients, the mean MGD stage was 2.27 ± 0.69 (range: 1–4), the mean OSDI score was 43.65 ± 20.86 (range: 7–93), the mean corneal staining grade (Oxford score) was 1.40 ± 0.77 (range: 7–21), the mean TBUT was 2.95 ± 2.63 s (range: 1–10 s), and the mean meiboscore of the lower eyelid was 1.21 ± 0.94 (range: 0–3) (Table 1).

Based on the one sample t-tests, the mean HDL value of the MGD patients was significantly higher than that of the general population ($P < 0.0001$); however, the mean TC level in patients with MGD was not statistically different from that of the general population ($P = 0.9153$). The mean TG and LDL values were significantly lower in the MGD group than in the general population group (TG: $P = 0.0064$; LDL: $P = 0.0282$) (Table 2).

Table 3 shows the distributions of MGD patients and those in the general population with abnormal lipid profiles based on the age ranges, as compared via one sample z-tests. In the age range of 45 to 65 years, a significantly higher rate of HDL abnormalities was observed in the MGD group than in the general population, although no significant differences were observed in terms of TC or TG abnormalities between the two groups across all age ranges.

Of the 95 MGD patients, the MGD subtype could be determined for 84 patients based on the meibum quality and expression test results. The lipid profiles of these patients were compared to determine whether they differed according to the MGD subtype. There was no statistically significant difference in lipid profile levels between any of the MGD subtypes (TC: $P = 0.765$, HDL: $P = 0.248$, LDL: $P = 0.343$, TG: $P = 0.703$). While not statistically significant, the mean HDL value was the highest in those with obstructive-type MGD. There was a statistically significant difference in the mean MGD stage among the three MGD subtypes ($P = 0.000$), and it was the highest in those with obstructive-type MGD (2.58 ± 0.62). The mean MG expression of patients with the hypersecretory subtype (6.89 ± 0.99) was significantly greater than

that of those with the obstructive (1.31 ± 1.18) or hyposecretory (1.91 ± 1.30) subtypes ($p=0.000$). The mean OSDI score was highest in the hyposecretory subtype, and there was a statistically significant difference in scores among the three subtypes ($p=0.008$). The mean meiboscore was the highest in the obstructive subtype, and there was a statistically significant difference among the three subtypes ($p = 0.041$). The mean age, TUBT, Oxford score for corneal staining, and LLT were not statistically different among the three subtypes (Table 4).

Discussion

Patients with MGD exhibited increased HDL levels compared with those of the controls in the normal population; this statistical significance remained after employing propensity score matching methods for age- and sex-matching. However, we observed no statistically significant differences in the lipid profile values among the three MGD subtypes. To our knowledge, this study is the first to compare serum lipid profiles according to MGD subtypes.

Also, while MGD patients had a significantly higher level of HDL than the age-and sex-matched controls, the TC levels did not differ between the two groups. The cause of this is unknown. Although HDL has cardioprotective effects, it may be a risk factor for MGD pathogenesis. Previous studies have reported significant correlations between dyslipidemia and MGD; however, the type of cholesterol associated with MGD has varied among studies. In most studies, the TC level was higher in the MGD group than in the control group⁵⁻⁷. Furthermore, several studies have reported a significant association between MGD and elevated blood levels of HDL^{5,8,9}. For example, Pina et al. showed in an observational, case-control, pilot study that MGD patients had a higher rate of hypercholesterolemia than the controls. In addition, MGD patients had significantly higher mean TC, LDL, and HDL levels. Moreover, based on logistic regression analysis, significantly higher levels of TC, LDL, and HDL have been found in MGD patients. Although the study conducted by Pina et al. differed from our own in terms of the age distribution, as their patient population was limited to young/middle-aged individuals (< 54 years), the high mean HDL value they reported in patients with MGD was consistent with our own study results. Dao et al. showed that patients with moderate to severe MGD ($n = 66$) had a higher incidence of elevated TC levels than those seen in the general population, with the component of the TC that most contributed to this increase being elevated HDL levels. However, in the comparison between the MGD group and the general population control group, their study was ambiguous about the methodology and statistical analysis related to the age- and sex-matching. In addition, since LDL generally accounts for most of the TC, it is difficult to conclude that the cause of the increase in TC observed in the MGD group resulted from the elevated HDL level.

This is the first study in which serum lipid profile levels were compared among the three MGD subtypes, and we confirmed that the mean HDL value was significantly higher in obstructive MGD patients than in those with other subtypes. Recently, HDL has received attention as a potential therapeutic target for the treatment of cardiovascular disease; however, considering our research and previous findings, HDL may negatively impact MGD pathogenesis, especially in the obstructive subtype. In general, the key role of HDL as a carrier of excess cellular cholesterol in the reverse cholesterol transportation pathway is

believed to be the protection it provides against the development of atherosclerosis¹⁰. HDL may also slow the progression of lesions by selectively decreasing the production of endothelial cell adhesion molecules that facilitate the uptake of cells into the vessel wall¹¹. HDL may, however, affect meibum production in sebaceous glands (i.e., MGs) via a mechanism that is distinct from that which mediates actions on blood vessels, although this requires further investigation through lipidomic studies¹².

Among the MGD subtypes, obstructive MGD is predominant. Likewise, in our study, obstructive-type MGD accounted for the largest proportion of patients. Obstructive MGD presents with reduced lipid secretion, combined with the production of highly viscous meibum due to duct orifice inflammation and hyperkeratinization¹³. Hypersecretory and hyposecretory MGD, on the other hand, are not characterized by the presence of severely viscous meibum. Some authors have suggested that the clinical features of hypersecretory MGD result from a damming of secretions due to partial obstruction and that this may represent an early stage of obstructive MGD¹⁴. Therefore, the MGD subtypes may share a common pathophysiology. In this study, although not statistically significant, the HDL level was highest in the obstructive type. There is a possibility that elevated HDL levels may contribute to an increase in the viscosity of the meibum as hyper/hypo-secretory MGD progresses to obstructive MGD, although it is unknown how the level of HDL changes in each MGD patient over a long period of time.

This study has several limitations. Firstly, this study used data from the 2012 KNHANES, which also included data from ophthalmic examinations. Excluding DED patients does not mean that the remaining subjects did not have some type of MGD or a related ocular disease, such as blepharitis. However, since LDL data were not collected in 2012, the LDL levels could not be compared based on this dataset alone. Therefore, the KNHANES data from 2015 were further analyzed as the control data for the LDL level comparisons. However, there were no ophthalmic examinations conducted in the 2015 KNHANES, and patients diagnosed with DED could not be excluded. Secondly, the sex ratio of the patients was very different, with the proportion of women being nearly 80%. According to Arita et al.¹⁵, the prevalence of symptomatic MGD (based on Japanese diagnostic criteria) was higher in men than in women (males: 42.1% versus females: 27.4%, $P = 0.0051$), although DED had a higher prevalence in women than in men (females: 41.7% versus males: 19.5%, $P < 0.0001$). In clinical practice, most patients who visit the hospital are symptomatic; therefore, it is thought that many female patients with both DED and MGD were enrolled in the study. Moreover, most of the previous studies have suggested that sex was not a significant confounding factor in the association between serum lipid levels and MGD. Thirdly, we included patients over the age of 65 years in this study, and the prevalence of MGD and dyslipidemia are known to increase with age⁹. Therefore, in the MGD and control groups, we confirmed that there were no differences in lipid levels, except for HDL levels, between the two groups according to age through a one sample z-test, as shown in Table 3. Fourthly, as a study with a retrospective and observational design, it is difficult to fully explain the cause-and-effect relationships between dyslipidemia and MGD. However, in order to overcome the limitations of this observational study, we employed propensity score matching using normal control patients from the KNHANES; this approach also allowed us to overcome the possibility of selection bias, similar to RCTs. The Korean population is also relatively homogenous in

terms of genetic and environmental variability, with a single race and a common climate and food culture. Thus, these potential confounding factors were unlikely to have affected the results, suggesting a very plausible association between MGD and serum lipid levels.

Conclusion

Our results suggest that MGD patients exhibit a higher degree of HDL abnormalities in their serum lipid profiles than individuals without MGD, although it was confirmed that there were no differences in serum lipid levels among the MGD subtypes, possibly due to their shared pathophysiologies. A large, prospective study is needed to control for additional variables to validate the possible statistically significant relationship between serum lipid levels and MGD. Further lipidomic studies should also be conducted to justify the early screening of MGD patients for the presence of dyslipidemia.

Declarations

Acknowledgements

This study was supported by a grant from the National Research Foundation of Korea (NRF) (2019R1F1A1061421) and by a grant from the Catholic University Yeouido St. Mary's Hospital in the program year of 2020. We would like to express our gratitude to Prof. Yong-gyu Park and Gyu-na Lee for providing support with the statistical analysis.

Author contributions

M.H., and K.S.N. contributed to the data analyses, text writing, and discussion of the results. J.S., S.P., K.H., H.S.H., H.S.K., and R.A. participated in the discussion of the results. All authors read and approved the final manuscript.

Funding

This study was supported by a grant from the National Research Foundation of Korea (NRF) (2019R1F1A1061421) and by a grant from the Catholic University Yeouido St. Mary's Hospital in the program year of 2020

Competing interests

The authors have no conflicts of interest to disclose

References

1. Shine, W. E. & McCulley, J. P. The role of cholesterol in chronic blepharitis. *Invest. Ophthalmol. Vis. Sci.* **32**, 2272–2280 (1991).

2. Shine, W. E. & McCulley, J. P. Role of wax ester fatty alcohols in chronic blepharitis. *Invest. Ophthalmol. Vis. Sci.* **34**, 3515–3521 (1993).
3. Butovich, I. A., Millar, T. J. & Ham, B. M. Understanding and analyzing meibomian lipids—a review. *Curr. Eye Res.* **33**, 405–420 <https://doi.org/10.1080/02713680802018419> (2008).
4. Shine, W. E. & McCulley, J. P. Polar lipids in human meibomian gland secretions. *Curr. Eye Res.* **26**, 89–94 <https://doi.org/10.1076/ceyr.26.2.89.14515> (2003).
5. Mathers, W. D., Shields, W. J., Sachdev, M. S., Petroll, W. M. & Jester, J. V. Meibomian gland dysfunction in chronic blepharitis. *Cornea.* **10**, 277–285 <https://doi.org/10.1097/00003226-199107000-00001> (1991).
6. Arita, R., Itoh, K., Inoue, K. & Amano, S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. *Ophthalmology.* **115**, 911–915 <https://doi.org/10.1016/j.optha.2007.06.031> (2008).
7. Nichols, K. K. *et al.* The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci* **52**, 1922–1929(2011).
8. Xiao, J. *et al.* Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and Severity. *Am. J. Ophthalmol.* **209**, 160–167 <https://doi.org/10.1016/j.ajo.2019.09.005> (2020).
9. Eom, Y. *et al.* Distribution and Characteristics of Meibomian Gland Dysfunction Subtypes: A Multicenter Study in South Korea. *Korean J Ophthalmol.* **33**, 205–213 <https://doi.org/10.3341/kjo.2018.0104> (2019).
10. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. *Biometrika.* **70**, 41–55 (1983).
11. Austin, P. C. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat. Med.* **33**, 1242–1258 <https://doi.org/10.1002/sim.5984> (2014).
12. Palmer, C. R. Encyclopedia of biostatistics. *BMJ.* **318**, 542 <https://doi.org/10.1136/bmj.318.7182.542> (1999).
13. Dao, A. H. *et al.* Association of dyslipidemia in moderate to severe meibomian gland dysfunction. *Am. J. Ophthalmol.* **150**, 371–375 e371, <https://doi.org/10.1016/j.ajo.2010.04.016> (2010).
14. Bukhari, A. A. Associations Between the Grade of Meibomian Gland Dysfunction and Dyslipidemia. *Ophthal Plast. Reconstr. Surg.* **29**, 101–103 <https://doi.org/10.1097/IOP.0b013e31827a007d> (2013).
15. Braich, P. S., Howard, M. K. & Singh, J. S. Dyslipidemia and its association with meibomian gland dysfunction. *Int. Ophthalmol.* **36**, 469–476 <https://doi.org/10.1007/s10792-015-0149-4> (2016).
16. Guliani, B. P., Bhalla, A. & Naik, M. P. Association of the severity of meibomian gland dysfunction with dyslipidemia in Indian population. *Indian J. Ophthalmol.* **66**, 1411–1416 https://doi.org/10.4103/ijo.IJO_1256_17 (2018).

17. Pinna, A., Blasetti, F., Zinellu, A., Carru, C. & Solinas, G. Meibomian gland dysfunction and hypercholesterolemia. *Ophthalmology*. **120**, 2385–2389 <https://doi.org/10.1016/j.ophtha.2013.05.002> (2013).
18. Brewer, H. B. Increasing HDL cholesterol levels. *N. Engl. J. Med.* **350**, 1491–1494 (2004). <https://doi.org/DOI 10.1056/NEJMp048023>
19. Barter, P. J., Baker, P. W. & Rye, K. A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. *Curr. Opin. Lipidol.* **13**, 285–288 <https://doi.org/10.1097/00041433-200206000-00008> (2002).
20. Osae, E. A. *et al.* Dyslipidemia and Meibomian Gland Dysfunction: Utility of Lipidomics and Experimental Prospects with a Diet-Induced Obesity Mouse Model. *Int. J. Mol. Sci.* **20**, <https://doi.org/10.3390/ijms20143505> (2019).
21. Knop, E., Knop, N., Millar, T., Obata, H. & Sullivan, D. A. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. *Invest. Ophthalmol. Vis. Sci.* **52**, 1938–1978, <https://doi.org/10.1167/iovs.10-6997c> (2011).
22. Foulks, G. N. & Bron, A. J. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. *Ocul. Surf.* **1**, 107–126 [https://doi.org/10.1016/s1542-0124\(12\)70139-8](https://doi.org/10.1016/s1542-0124(12)70139-8) (2003).
23. Arita, R. *et al.* Meibomian Gland Dysfunction and Dry Eye Are Similar but Different Based on a Population-Based Study: The Hirado-Takushima Study in Japan. *Am. J. Ophthalmol.* **207**, 410–418 <https://doi.org/10.1016/j.ajo.2019.02.024> (2019).

Tables

Table 1

Clinical characteristics of patients who applied propensity score methods (1:5).

Characteristics	MGD patients	Control patients	P-value
	values		
No. of patients	95	475	
Age(year)	57.513.2	56.412.7	0.8722
Age(year) range	19-86	19-80	
Age distribution			
<45(%)	16(16.8)	85(17.9)	0.5613
45-64(%)	47(49.5)	256(53.9)	
>65(%)	32(32.7)	134(28.2)	
Gender			
Men (%)	15(15.8)	70(14.7)	0.7926
Women (%)	80(84.2)	405(85.3)	
Lipid profile			
Total cholesterol(mg/dL)	193.5±33.9	196±37.3	0.4685
(normal value: < 200)			
Triglyceride(mg/dL)	127.2±75.3	135.6±133.5	0.5530
(normal value: 34-143)			
HDL(mg/dL)	63.1±14.7	52.1±12.5	<.0001
(normal value: 40-60)			
LDL(mg/dL)	109.7±29.5	116.4±32.5*	0.0713*
(normal value: <140)			
MGD stage	2.270.69 (1-4)		
OSDI score	43.6520.86 (7-93)	-	
IOP(mmHg)	14.483.05 (7-21)	-	
Oxford score	1.400.77 (0-3)	-	
TBUT(sec)	2.952.63 (1-10)	-	
Meiboscore	1.210.94 (0-3)	-	

Values are presented as mean Standard deviation (range) or number (%).

HDL= high-density lipoprotein, LDL= Low-density lipoprotein

OSDI = Ocular surface disease index, IOP = intraocular pressure, TUBT= tear film break-up time

* Since KNHAES did not conduct an LDL survey in 2012, we further analyzed the LDL data from 2015.

Table 2

One sample t-test results of the weighted lipid profile mean value between MGD group and control group.

	Df	t-statistics	P-value
H0 : Total Cholesterol = 196.4	94	-0.99	0.3223
H0 : Triglycerides = 148.7	94	-2.79	0.0064
H0 : HDL = 52.6	94	6.91	<.0001
H0 : LDL = 116.7*	88*	-2.23*	0.0282*

Df = degree of freedom

* Since KNHAES did not conduct an LDL survey in 2012, we further analyzed the LDL data from 2015.

Table 3

The distribution of MGD patients with abnormal lipid profile according to the age range was compared with the average value of the general population using one sample z test.

Lipid profile	Age range	n	event	%	p-value
Total Cholesterol, >200	<45	16	4	25	0.3543
	45-64	47	23	48.9	0.6027
	≥65	32	12	37.5	0.5192
Triglycerides >150	<45	16	3	18.8	0.6716
	45-64	47	11	23.4	0.1715
	≥65	32	10	31.3	0.6361
HDL <40 (40-60)	<45	16	0	0	-
	45-64	47	3	6.4	0.0406
	≥65	32	2	6.3	0.1485
LDL >130	<45	15*	2*	13.3*	0.6962*
	45-64	44*	11*	25*	0.1435*
	≥65	30*	6*	20*	0.2449*

HDL = high-density lipoprotein, LDL = Low-density lipoprotein

* Since KNHAES did not conduct an LDL survey in 2012, we further analyzed the LDL data from 2015.

Table 4

Comparison of patient characteristics and serum lipid profile according to MGD subtype.

		MGD subtype (N=84)			P-value
		Obstructive (N=45)	Hyposecretory (N=11)	Hypersecretory (N=28)	
Age		56.8012.34	52.3610.39	57.5715.67	0.497
Sex	Male	8	2	3	0.680
	Female	37	9	25	
MGD stage		2.58 0.62	2.27 0.64	1.82 0.54	0.000
OSDI score		4			0.008
TBUT(sec)		2			0.212
Oxford stain score		0.93			0.304
MG expression		1.31			0.000
LLT		81.36	81.00	86.407	0.581
Meiboscore		1.490.91	1.09	0.93 0.68	0.041
Total cholesterol		187.89			0.765
HDL		65.39			0.248
LDL		104.93		112.08	0.343
TG		126.89			0.703

Values are presented as mean Standard deviation (range) or number (%).

Figures

Figure 1

General population selection flow diagram for comparison of lipid profile between MGD and control patients.

Figure 2

Mean value and standard deviation of lipid profile (TC, TG, HDL, LDL) of MGD and control patients. The HDL level of MGD patients was statistically significantly higher than that of the control group ($P < .0001$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementTable1.docx](#)